商品化血小板病原体灭活技术的应用现状及质量评价  

Current Status of Application and Quality Evaluation of Commercial Platelet Pathogen Reduction Technology

作　　者：樊斌 杨春晖 李彬 陈利民 FAN Bin;YANG Chun-Hui;UI Bin;CHEN Li-Min(Provincial Key Laboratory for Transfusion-Transmitted Ingfectious Diseases,Institute of Blood Traunsfusion,Chinese Academy of Medical Sciences and Peking Union Medical College,Chengdu 610062,Sichuan Province,China;The Joint Laborulory an Transfusion-Transmitted Diseases(TTD)Benween Institute of Blood Transfusion,Chinese Academy of Medical Sciences,Nonning Blood Center,Narming 530007,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]中国医学科学院、北京协和医学院输血研究所输血传播传染病省级重点实验室,四川成都610062 [2]中国医学科学院输血研究所、南宁中心血站输血传播疾病(TTD)联合实验室,南宁中心血站,广西南宁530007

出　　处：《中国实验血液学杂志》2024年第4期1300-1304,共5页Journal of Experimental Hematology

基　　金：中国输血协会圣湘输血医学发展基金(CSBT-SX-2022-01)。

摘　　要：随着输血医学的发展,血小板病原体污染问题越来越受到行业的关注。目前病原体灭活技术(PRT)已经成功应用于血小板并取得了很好的效果。本文对已经商品化的血小板PRT研究进展进行概述,对血小板PRT的应用现状、临床前机制研究、临床队列研究及替代或补充策略等方面的内容进行综合分析并提出建议,为保障我国血液安全、开发适用于我国国情的血小板PRT产品提供科学依据。With the development of transfusion medicine,platelet pathogen contamination is of increasing concern to the industry.Currently,pathogen reduction technology(PRT)has been successfully applied to platelets and achieved good results.This paper provides an overview of the research progress of commercial platelet PRT,a comprehensive analysis of the current application status of platelet PRT,preclinical mechanism studies,clinical cohort studies and alternative or complementary strategies,and makes recommendations to provide a scientific basis for safeguarding blood safety in China and developing platelet PRT products applicable to our national conditions.

关 键 词：输血传播 病原体灭活 血小板输注 

分 类 号：R457.1[医药卫生—治疗学]